HGG-TCP High Grade Glioma Tumor Concentrations of protein kinase inhibitors
- Conditions
- Targeted TherapyHigh-grade gliomaKinase inhibitorAngiogenesis Targeted therapieHooggradig glioomKinase remmerAngiogenese
- Registration Number
- NL-OMON28204
- Lead Sponsor
- VU University Medical CenterDe Boelelaan 117, 1081 HV Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. Patients without a history of brain tumor
2. Initial brain MR-scan suggesting a high grade glioma, according to the interpretation of an expert neuroradiologist
Exclusion Criteria
1. Patients receiving prior chemotherapy, radiotherapy or anti-angiogenic therapy
2. Use of anti-coagulant therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine PKI and active metabolites concentrations in tumor tissue after approximately two weeks of treatment in patients with a newly diagnosed HGG.
- Secondary Outcome Measures
Name Time Method 1) To determine the correlation of PKI and active metabolites concentrations in tumor with PKI and active metabolites concentrations in plasma- and CSF after approximately two weeks of treatment.<br /> <br>2) To test the feasibility of determining the (phospho)proteomic profiles and kinase activity profiles in tumor tissue and CSF after two weeks of treatment. <br /><br>3) To determine whether approximately two weeks of treatment with PKIs induces significant difference of the (phospho)proteomic profiles and kinase activities of tumor tissue from study patients and from patients in a control group (without PKI treatment prior to resection).